Beigene Ltd (NASDAQ:BGNE) had its Buy rating reiterated by Maxim Group with a $215.00 price target

ME Staff
-
0

Analyst Ratings For Beigene Ltd (NASDAQ:BGNE)

Today, Maxim Group reiterated its Buy rating on Beigene Ltd (NASDAQ:BGNE) with a price target of $215.00.

There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Beigene Ltd (NASDAQ:BGNE) is Buy with a consensus target price of $180.9583 per share, a potential 13.11% upside.

Some recent analyst ratings include

  • 9/20/2018-Beigene Ltd (NASDAQ:BGNE) had its Buy rating reiterated by Maxim Group with a $215.00 price target
  • 9/19/2018-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Buy rating and $160.75 price target
  • 9/17/2018-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Buy rating
  • 8/10/2018-Beigene Ltd (NASDAQ:BGNE) had its Buy rating reiterated by Cowen
  • 5/14/2018-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Outperform ➝ Outperform rating

Recent Insider Trading Activity For Beigene Ltd (NASDAQ:BGNE)
Beigene Ltd (NASDAQ:BGNE) has insider ownership of 14.10% and institutional ownership of 77.87%.

  • On 9/4/2018 Jane Huang, CMO, sold 2,911 with an average share price of $174.60 per share and the total transaction amounting to $508,260.60.
  • On 8/30/2018 Donald W Glazer, Director, sold 2,000 with an average share price of $179.00 per share and the total transaction amounting to $358,000.00.
  • On 8/23/2018 Amy C Peterson, CMO, sold 5,769 with an average share price of $169.12 per share and the total transaction amounting to $975,653.28.
  • On 8/13/2018 Xiaodong Wang, Director, sold 3,449 with an average share price of $158.77 per share and the total transaction amounting to $547,597.73.
  • On 8/2/2018 Bros. Advisors Lp Baker, Director, bought 5,814,100 with an average share price of $108.00 per share and the total transaction amounting to $627,922,800.00.
  • On 7/16/2018 John Oyler, CEO, sold 2,550 with an average share price of $164.12 per share and the total transaction amounting to $418,506.00.
  • On 3/19/2018 Howard Liang, CFO, sold 40,000 with an average share price of $160.27 per share and the total transaction amounting to $6,410,800.00.

About Beigene Ltd (NASDAQ:BGNE)
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.

Recent Trading Activity for Beigene Ltd (NASDAQ:BGNE)
Shares of Beigene Ltd closed the previous trading session at 160,20 −3,30 2,02 % with 114593 shares trading hands.